RASAGILINE MESYLATE Drug Patent Profile
✉ Email this page to a colleague
When do Rasagiline Mesylate patents expire, and when can generic versions of Rasagiline Mesylate launch?
Rasagiline Mesylate is a drug marketed by Alkem Labs Ltd, Apotex Inc, Aurobindo Pharma Usa, Carnegie, Chartwell Rx, Indoco, Macleods Pharms Ltd, Micro Labs, Orbion Pharms, Skg Pharma, and Watson Labs Inc. and is included in eleven NDAs.
The generic ingredient in RASAGILINE MESYLATE is rasagiline mesylate. There are eighteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the rasagiline mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rasagiline Mesylate
A generic version of RASAGILINE MESYLATE was approved as rasagiline mesylate by ORBION PHARMS on March 15th, 2016.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RASAGILINE MESYLATE?
- What are the global sales for RASAGILINE MESYLATE?
- What is Average Wholesale Price for RASAGILINE MESYLATE?
Summary for RASAGILINE MESYLATE
| US Patents: | 0 |
| Applicants: | 11 |
| NDAs: | 11 |
| Finished Product Suppliers / Packagers: | 9 |
| Raw Ingredient (Bulk) Api Vendors: | 113 |
| Clinical Trials: | 14 |
| Patent Applications: | 197 |
| Drug Prices: | Drug price information for RASAGILINE MESYLATE |
| DailyMed Link: | RASAGILINE MESYLATE at DailyMed |
Recent Clinical Trials for RASAGILINE MESYLATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Teva Pharmaceutical Industries | Phase 1 |
| Teva Branded Pharmaceutical Products R&D, Inc. | Phase 1 |
| Technische Universität Dresden | Phase 4 |
Pharmacology for RASAGILINE MESYLATE
| Drug Class | Monoamine Oxidase Inhibitor |
| Mechanism of Action | Monoamine Oxidase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for RASAGILINE MESYLATE
Paragraph IV (Patent) Challenges for RASAGILINE MESYLATE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| AZILECT | Tablets | rasagiline mesylate | 0.5 mg and 1 mg | 021641 | 5 | 2010-05-17 |
US Patents and Regulatory Information for RASAGILINE MESYLATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkem Labs Ltd | RASAGILINE MESYLATE | rasagiline mesylate | TABLET;ORAL | 201889-001 | Oct 30, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Orbion Pharms | RASAGILINE MESYLATE | rasagiline mesylate | TABLET;ORAL | 201970-002 | Mar 15, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Carnegie | RASAGILINE MESYLATE | rasagiline mesylate | TABLET;ORAL | 201942-001 | Nov 18, 2021 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
